The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase |
| |
Authors: | Khosravan Reza Kukulka Michael J Wu Jing-Tao Joseph-Ridge Nancy Vernillet Laurent |
| |
Affiliation: | TAP Pharmaceutical Products Inc, Lake Forest, Illinois, USA. |
| |
Abstract: | Febuxostat is a novel nonpurine selective inhibitor of xanthine oxidase, which is currently being developed for the management of hyperuricemia in patients with gout. The effect of age and gender on the pharmacokinetics, pharmacodynamics, and safety of once-daily oral febuxostat 80 mg was assessed in healthy male and female subjects after 7 days. Following multiple dosing with febuxostat, there were no statistically significant differences in the plasma or urinary pharmacokinetic or pharmacodynamic parameters between subjects aged 18 to 40 years and >or=65 years. Although unbound peak concentration (C(max,u)) and area under the concentration-time curve (AUC(24,u)) for febuxostat were higher in women as compared with men (31.5 vs 23.6 ng/mL, P
|
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|